clinical trial · NCT02951598
A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease (AD)
Eli Lilly and Company·—·active not recruiting·n = 1,400
Alzheimer DiseaseMild Cognitive ImpairmentFlorbetapir F 18 PET Scan
brief summary
The purpose of this study is to learn about health care use, costs, and clinical outcomes over time for amyloid positive participants with early stages of AD in the United States. This study is for research purposes only, and is not intended to treat any medical condition. No study therapy(ies) for AD will be administered.
started
Oct 29, 2016
primary completion
Jan 30, 2021
completion
Apr 28, 2026
last updated
Oct 24, 2025
official title
Longitudinal Cohort Study of Resource Use and Cost of Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease in the United States (GERAS-US)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol